NCT05666687View on ClinicalTrials.gov

An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 11, 2023

Primary Completion Date

November 7, 2023

Study Completion Date

November 7, 2023

Conditions
Major Depressive Disorder
Interventions
DRUG

MIJ821

MIJ821 will be administered as an i.v. infusion

Trial Locations (1)

HA1 3UJ

Novartis Investigative Site, Watford Road Harrow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY